Versatile IDegAsp

For people with type 2 diabetes (T2DM) who fail to achieve optimal blood glucose levels with basal insulin and oral…

Read More
CPD POINTS: 2

Long-term efficacy and safety of ruxolitinib in patients with polycythaemia vera

The results of the five year phase 3 RESPONSE study showed that ruxolitinib, a Janus kinase (JAK) 1 and 2…

Read More
CPD POINTS: 2

TPO-RA: Game-changers in the treatment of immune thrombocytopaenia

Immune thrombocytopenia (ITP) – previously referred to as idiopathic thrombocytopenic purpura – is an autoimmune bleeding disorder characterised by abnormally low…

Read More
CPD POINTS: 1

Weight-loss medications: how do they measure up?

As global waistlines expand, the demand for weight-loss drugs follows suit. While the US Food and Drug Administration (FDA) has…

Read More
CPD POINTS: 1

Protected: Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency

The objective of this study was to analyze the current evidence for the use of pancreatic enzyme replacement therapy (PERT)…

Read More
CPD POINTS: 1

SCALE-ing obesity

Obesity management is more than numbers on a scale, it is about improving health – Dr Sue Pedersen 

IDegLira: Simplifying T2DM management

According to a survey by the International Diabetes Federation, the prevalence if T2DM is expected to exceed 10% of the…

The challenge of obesity in the psychiatric population

SA has the highest overweight and obesity rate in sub-Saharan Africa, with up to 70% of women and a third…

The future of healthcare is green

Dr Ted Schettler has been a staunch advocate of environmental health and justice for the past 30 years. He is…